Literature DB >> 7996472

Selective antagonism of opioid analgesia by a sigma system.

C C Chien1, G W Pasternak.   

Abstract

(+)Pentazocine antagonizes morphine analgesia as potently as its (-)-isomer, ruling out an opioid receptor mechanism of action and suggesting, which suggests a role for sigma 1 receptors. Systemic (+) pentazocine also reverses supraspinal or spinal morphine analgesia. 1,3-Di(2-tolyl)guanidine, a sigma ligand with no appreciable opioid receptor affinity, antagonizes morphine analgesia. The actions of both (+)pentazocine and 1,3-di(2-tolyl)guanidine are reversed by haloperidol, which has high affinity for both sigma and D2 receptors, but not by the D2-selective antagonist (-)sulpiride, which lacks activity at sigma sites. The antiopioid sigma system is tonically active. Haloperidol, but not (-)sulpiride, decreases morphine ED50 almost 2-fold. The antiopioid system modulates only mu analgesia. Unlike analgesia, (+)pentazocine does not influence morphine's inhibition of gastrointestinal transit or lethality. (+)Pentazocine also antagonizes kappa 1, kappa 3 and delta analgesia through sigma mechanisms in a haloperidol-sensitive manner. (-)Sulpiride is inactive. Alone, haloperidol enhances kappa 1, kappa 3 and delta analgesia more dramatically than morphine, which indicates that the sigma system is active against all opioid analgesic systems. Sigma systems are responsible for some strain differences in kappa receptor sensitivity. Unlike CD-1 mice, BALB-C mice are relatively insensitive toward the kappa 1 agent U50,488H and the kappa 3 analgesic naloxone benzoylhydrazone. Blockade of the sigma system with haloperidol eliminates these strain differences. In conclusion, sigma 1 systems functionally antagonize opioid analgesia without affecting morphine's effects on gastrointestinal transit or lethality. The antiopioid sigma system is tonically active and is more active against kappa analgesia than mu.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996472

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization.

Authors:  L Romero; D Zamanillo; X Nadal; R Sánchez-Arroyos; I Rivera-Arconada; A Dordal; A Montero; A Muro; A Bura; C Segalés; M Laloya; E Hernández; E Portillo-Salido; M Escriche; X Codony; G Encina; J Burgueño; M Merlos; J M Baeyens; J Giraldo; J A López-García; R Maldonado; C R Plata-Salamán; J M Vela
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

3.  Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies.

Authors:  Montserrat Abadias; Marisol Escriche; Anna Vaqué; Mariano Sust; Gregorio Encina
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 4.  The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems.

Authors:  Tsung-Ping Su; Tzu-Chieh Su; Yoki Nakamura; Shang-Yi Tsai
Journal:  Trends Pharmacol Sci       Date:  2016-02-09       Impact factor: 14.819

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 6.  Sigma-1 receptor and inflammatory pain.

Authors:  Georgia Gris; Enrique José Cobos; Daniel Zamanillo; Enrique Portillo-Salido
Journal:  Inflamm Res       Date:  2015-04-23       Impact factor: 4.575

7.  Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action.

Authors:  V Theodorou; M Chovet; H Eutamene; H Fargeau; M Dassaud; M Toulouse; C Bihoreau; F J Roman; L Bueno
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 8.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice.

Authors:  Cruz M Cendán; José M Pujalte; Enrique Portillo-Salido; José M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

10.  Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding.

Authors:  Felix J Kim; Ivanka Kovalyshyn; Maxim Burgman; Claire Neilan; Chih-Cheng Chien; Gavril W Pasternak
Journal:  Mol Pharmacol       Date:  2010-01-20       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.